Allosteric modulation of endogenous metabolites as an avenue for drug discovery.

scientific article published on 10 May 2012

Allosteric modulation of endogenous metabolites as an avenue for drug discovery. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1124/MOL.112.079319
P698PubMed publication ID22576254
P5875ResearchGate publication ID224939507

P50authorArthur ChristopoulosQ18977850
Patrick M. SextonQ39936838
Denise WoottenQ43294588
Celine ValantQ56938593
Francis S WillardQ87454852
Kyle W SloopQ87454855
Lauren T MayQ96202346
Emilia E SavageQ114366388
Aaron D ShowalterQ114366398
James FicorilliQ114366399
P433issue2
P921main subjectdrug discoveryQ1418791
P304page(s)281-290
P577publication date2012-05-10
P1433published inMolecular PharmacologyQ1943386
P1476titleAllosteric modulation of endogenous metabolites as an avenue for drug discovery
P478volume82

Reverse relations

cites work (P2860)
Q39024066A Duplexed High-Throughput Screen to Identify Allosteric Modulators of the Glucagon-Like Peptide 1 and Glucagon Receptors
Q42704926A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification.
Q34545629Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor.
Q41143099Allosteric Optical Control of a Class B G-Protein-Coupled Receptor.
Q34539431Allosteric transition: a comparison of two models
Q37098923Differential Requirement of the Extracellular Domain in Activation of Class B G Protein-coupled Receptors
Q38125563Emerging paradigms in GPCR allostery: implications for drug discovery
Q34734229Expression, regulation and putative nutrient-sensing function of taste GPCRs in the heart
Q33615669Genetically encoded photocross-linkers determine the biological binding site of exendin-4 peptide in the N-terminal domain of the intact human glucagon-like peptide-1 receptor (GLP-1R)
Q28067465Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes
Q34454930Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery.
Q52315660Insights from molecular dynamics simulations to exploit new trends for the development of improved opioid drugs.
Q39213738Investigating G protein signalling bias at the glucagon-like peptide-1 receptor in yeast
Q37050373Minireview: Signal bias, allosterism, and polymorphic variation at the GLP-1R: implications for drug discovery
Q28551517Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation
Q33697296Myricetin: a potent approach for the treatment of type 2 diabetes as a natural class B GPCR agonist
Q52313686New Paradigms in Adenosine Receptor Pharmacology: Allostery, Oligomerization and Biased Agonism.
Q28834277Positive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles
Q27027736Positive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medications
Q41239519Potent Prearranged Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor.
Q37183072Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors
Q37237174Real-time characterization of cannabinoid receptor 1 (CB1 ) allosteric modulators reveals novel mechanism of action
Q38736252Recent Advances in the Realm of Allosteric Modulators for Opioid Receptors for Future Therapeutics
Q38077226Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function.
Q38081692Signalling bias in new drug discovery: detection, quantification and therapeutic impact.
Q88697656Small-Molecule Positive Allosteric Modulators of the β2-Adrenoceptor Isolated from DNA-Encoded Libraries
Q52309488Structural basis for GPR40 allosteric agonism and incretin stimulation.
Q97636433Structural insights into probe-dependent positive allosterism of the GLP-1 receptor
Q34657381Sucralose, a synthetic organochlorine sweetener: overview of biological issues
Q26999386Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System

Search more.